Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAE005 + Afuresertib + Nab-paclitaxel in Advanced Solid Tumors and mTNBC
CTR20210500Phase 2Completed
- Sponsor
- Laekna
- Start
- Mar 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of FAZ053, afuresertib, paclitaxel in Nonhematologic neoplasms, triple-negative breast cancer (TNBC), sponsored by Laekna. Started Mar 2021; status: completed.
02
Drugs
FAZ053afuresertibpaclitaxel
03
Conditions
Nonhematologic neoplasmstriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20210500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210500.